<p>Pyxis Oncology, Inc.（納斯達克代碼：PYXS - 獲取免費報告）獲得了七家覆蓋該公司的券商一致推薦的 “適度買入” 評級，Marketbeat.com 報道。一位研究分析師對該股票給予了賣出評級，一位給予了持有評級，五位給予了買入評級。在過去一年中，對該股票發佈評級的券商的平均 12 個月目標價格為 7.20 美元。</p>
<p>獲取 <strong>Pyxis Oncology</strong> 的提醒：</p>
<p>多家研究機構已對 PYXS 發佈了報告。華爾街禪在 12 月 20 日的研究報告中將 Pyxis Oncology 的股票評級從 “持有” 下調至 “賣出”。古根海姆在 11 月 4 日的研究報告中將 Pyxis Oncology 的目標價格從 5.00 美元上調至 7.00 美元，並給予該公司 “買入” 評級。韋斯評級在 10 月 8 日的研究報告中重申了對 Pyxis Oncology 的 “賣出（d-）” 評級。扎克斯研究在 11 月 4 日的研究報告中將 Pyxis Oncology 的評級從 “強力買入” 下調至 “持有”。最後，斯蒂芬斯在 11 月 24 日的研究報告中將 Pyxis Oncology 的目標價格從 5.00 美元上調至 8.00 美元，並給予該股票 “超配” 評級。</p>
<p><strong>查看我們最新的 Pyxis Oncology 股票分析</strong></p>
<h2>Pyxis Oncology 股票表現</h2>
<p>PYXS 的股票在週五開盤價為 1.15 美元。該公司的 50 日移動平均價格為 3.59 美元，200 日移動平均價格為 2.37 美元。該公司的市值為 7160 萬美元，市盈率為-0.72，貝塔值為 1.45。Pyxis Oncology 的 52 周低點為 0.83 美元，52 周高點為 5.55 美元。</p>
<p>Pyxis Oncology（納斯達克代碼：PYXS - 獲取免費報告）最近在 11 月 3 日發佈了季度財報。該公司報告每股收益（EPS）為-0.35 美元，超出市場共識預期的-0.36 美元，超出幅度為 0.01 美元。整體來看，研究分析師預測 Pyxis Oncology 在當前年度將發佈-1.04 美元的每股收益。</p>
<h2>對 Pyxis Oncology 的對沖基金看法</h2>
<p>機構投資者最近調整了對該股票的持有情況。Catalyst Funds Management Pty Ltd 在第二季度購買了 Pyxis Oncology 的新頭寸，價值約為 26,000 美元。Kingstone Capital Partners Texas LLC 在第二季度獲得了 Pyxis Oncology 的新股份，價值 37,000 美元。XTX Topco Ltd 在第二季度購買了 Pyxis Oncology 的新頭寸，價值 40,000 美元。Velan Capital Investment Management LP 在第二季度獲得了 Pyxis Oncology 的新頭寸，價值 44,000 美元。最後，Persistent Asset Partners Ltd 在第三季度購買了 Pyxis Oncology 的新股份，價值 77,000 美元。目前，39.09% 的股票由機構投資者和對沖基金持有。</p>
<h2>關於 Pyxis Oncology</h2>
<p>（獲取免費報告）</p>
<p>Pyxis Oncology（納斯達克代碼：PYXS）是一家臨牀階段的生物技術公司，專注於靶向腫瘤治療的發現和開發。該公司的平台以抗體藥物偶聯物（ADCs）為中心，直接將強效的有絲分裂抑制劑輸送到癌細胞，利用新型載荷設計來干擾細胞分裂。通過將高度特異性的抗體與創新的細胞毒性藥物結合，Pyxis Oncology 旨在改善治療窗口並減少傳統化療常見的非靶向毒性。</p>
<p>自成立以來，Pyxis Oncology 已建立了一條針對多種實體腫瘤抗原的早期 ADC 候選藥物管線。</p>
<h2>另見</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Pyxis Oncology</li>
<li>黃金警報</li>
<li>如果你在美國銀行賬户中存現金……請立即閲讀</li>
<li>沒有人告訴你的 100 萬億美元的人工智能故事</li>
<li>關於中國的震撼揭露</li>
<li>請勿刪除，立即閲讀</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFlYUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFlYUw"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Pyxis Oncology 嗎？</h2>
<p>在你考慮 Pyxis Oncology 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Pyxis Oncology 並不在名單上。</p>
<p>雖然 Pyxis Oncology 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

PYXS

<p>Pyxis Oncology, Inc.（納斯達克代碼：PYXS）獲得了七家券商的共識推薦為 “適度買入”。一位分析師將其評級為賣出，一位為持有，五位為買入。12 個月的平均目標價為 7.20 美元。最近的報告顯示評級不一，一些公司下調了評級，而另一些則提高了目標價。該股票開盤價為 1.15 美元，市值為 7160 萬美元。機構投資者持有該股票的 39.09%。Pyxis 專注於開發使用抗體藥物偶聯物的靶向腫瘤治療</p>

<p>Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) has been assigned a consensus recommendation of &#34;Moderate Buy&#34; from the seven brokerages that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have given a buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $7.20.</p>
<div class="lb-trans"><p>Pyxis Oncology, Inc.（納斯達克代碼：PYXS - 獲取免費報告）獲得了七家覆蓋該公司的券商一致推薦的 “適度買入” 評級，Marketbeat.com 報道。一位研究分析師對該股票給予了賣出評級，一位給予了持有評級，五位給予了買入評級。在過去一年中，對該股票發佈評級的券商的平均 12 個月目標價格為 7.20 美元。</p>
</div><p>Get <strong>Pyxis Oncology</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Pyxis Oncology</strong> 的提醒：</p>
</div><p>A number of research firms have issued reports on PYXS. Wall Street Zen downgraded shares of Pyxis Oncology from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday, December 20th. Guggenheim raised their price objective on shares of Pyxis Oncology from $5.00 to $7.00 and gave the company a &#34;buy&#34; rating in a research note on Tuesday, November 4th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Pyxis Oncology in a research report on Wednesday, October 8th. Zacks Research lowered Pyxis Oncology from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Tuesday, November 4th. Finally, Stephens lifted their price objective on Pyxis Oncology from $5.00 to $8.00 and gave the stock an &#34;overweight&#34; rating in a research note on Monday, November 24th.</p>
<div class="lb-trans"><p>多家研究機構已對 PYXS 發佈了報告。華爾街禪在 12 月 20 日的研究報告中將 Pyxis Oncology 的股票評級從 “持有” 下調至 “賣出”。古根海姆在 11 月 4 日的研究報告中將 Pyxis Oncology 的目標價格從 5.00 美元上調至 7.00 美元，並給予該公司 “買入” 評級。韋斯評級在 10 月 8 日的研究報告中重申了對 Pyxis Oncology 的 “賣出（d-）” 評級。扎克斯研究在 11 月 4 日的研究報告中將 Pyxis Oncology 的評級從 “強力買入” 下調至 “持有”。最後，斯蒂芬斯在 11 月 24 日的研究報告中將 Pyxis Oncology 的目標價格從 5.00 美元上調至 8.00 美元，並給予該股票 “超配” 評級。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on Pyxis Oncology</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 Pyxis Oncology 股票分析</strong></p>
</div><h2>Pyxis Oncology Stock Performance</h2>
<div class="lb-trans"><h2>Pyxis Oncology 股票表現</h2>
</div><p>Shares of PYXS opened at $1.15 on Friday. The business's fifty day moving average price is $3.59 and its two-hundred day moving average price is $2.37. The firm has a market capitalization of $71.60 million, a price-to-earnings ratio of -0.72 and a beta of 1.45. Pyxis Oncology has a 52 week low of $0.83 and a 52 week high of $5.55.</p>
<div class="lb-trans"><p>PYXS 的股票在週五開盤價為 1.15 美元。該公司的 50 日移動平均價格為 3.59 美元，200 日移動平均價格為 2.37 美元。該公司的市值為 7160 萬美元，市盈率為-0.72，貝塔值為 1.45。Pyxis Oncology 的 52 周低點為 0.83 美元，52 周高點為 5.55 美元。</p>
</div><p>Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last issued its quarterly earnings results on Monday, November 3rd. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.01. As a group, research analysts forecast that Pyxis Oncology will post -1.04 EPS for the current year.</p>
<div class="lb-trans"><p>Pyxis Oncology（納斯達克代碼：PYXS - 獲取免費報告）最近在 11 月 3 日發佈了季度財報。該公司報告每股收益（EPS）為-0.35 美元，超出市場共識預期的-0.36 美元，超出幅度為 0.01 美元。整體來看，研究分析師預測 Pyxis Oncology 在當前年度將發佈-1.04 美元的每股收益。</p>
</div><h2>Hedge Funds Weigh In On Pyxis Oncology</h2>
<div class="lb-trans"><h2>對 Pyxis Oncology 的對沖基金看法</h2>
</div><p>Institutional investors have recently modified their holdings of the stock. Catalyst Funds Management Pty Ltd bought a new position in Pyxis Oncology during the 2nd quarter worth approximately $26,000. Kingstone Capital Partners Texas LLC acquired a new stake in Pyxis Oncology in the second quarter worth $37,000. XTX Topco Ltd bought a new position in shares of Pyxis Oncology during the second quarter worth $40,000. Velan Capital Investment Management LP acquired a new position in shares of Pyxis Oncology in the 2nd quarter valued at $44,000. Finally, Persistent Asset Partners Ltd bought a new stake in shares of Pyxis Oncology in the 3rd quarter valued at $77,000. 39.09% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>機構投資者最近調整了對該股票的持有情況。Catalyst Funds Management Pty Ltd 在第二季度購買了 Pyxis Oncology 的新頭寸，價值約為 26,000 美元。Kingstone Capital Partners Texas LLC 在第二季度獲得了 Pyxis Oncology 的新股份，價值 37,000 美元。XTX Topco Ltd 在第二季度購買了 Pyxis Oncology 的新頭寸，價值 40,000 美元。Velan Capital Investment Management LP 在第二季度獲得了 Pyxis Oncology 的新頭寸，價值 44,000 美元。最後，Persistent Asset Partners Ltd 在第三季度購買了 Pyxis Oncology 的新股份，價值 77,000 美元。目前，39.09% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>About Pyxis Oncology</h2>
<div class="lb-trans"><h2>關於 Pyxis Oncology</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Pyxis Oncology NASDAQ: PYXS is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company's platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.</p>
<div class="lb-trans"><p>Pyxis Oncology（納斯達克代碼：PYXS）是一家臨牀階段的生物技術公司，專注於靶向腫瘤治療的發現和開發。該公司的平台以抗體藥物偶聯物（ADCs）為中心，直接將強效的有絲分裂抑制劑輸送到癌細胞，利用新型載荷設計來干擾細胞分裂。通過將高度特異性的抗體與創新的細胞毒性藥物結合，Pyxis Oncology 旨在改善治療窗口並減少傳統化療常見的非靶向毒性。</p>
</div><p>Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.</p>
<div class="lb-trans"><p>自成立以來，Pyxis Oncology 已建立了一條針對多種實體腫瘤抗原的早期 ADC 候選藥物管線。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Pyxis Oncology</li>
<li>GOLD ALERT</li>
<li>If You Keep Cash In A U.S. Bank Account… Read This NOW</li>
<li>The $100 Trillion AI Story No One Is Telling You</li>
<li>Bombshell Exposé on China Strikes</li>
<li>Do not delete, read immediately</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Pyxis Oncology</li>
<li>黃金警報</li>
<li>如果你在美國銀行賬户中存現金……請立即閲讀</li>
<li>沒有人告訴你的 100 萬億美元的人工智能故事</li>
<li>關於中國的震撼揭露</li>
<li>請勿刪除，立即閲讀</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFlYUw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=PYXS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Pyxis Oncology Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Pyxis Oncology 嗎？</h2>
</div><p>Before you consider Pyxis Oncology, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Pyxis Oncology 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pyxis Oncology wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Pyxis Oncology 並不在名單上。</p>
</div><p>While Pyxis Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Pyxis Oncology 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Pyxis Oncology, Inc.（納斯達克股票代碼：PYXS）被券商一致推薦為 “適度買入”